Ibrexafungerp

FDA APPROVAL DATE: 06/01/2021

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Bosentan, Carbamazepine, CYP3A inducers, CYP3A inhibitors, Efavirenz, Etravirine, Itraconazole, Ketoconazole, long acting barbiturates , Phenytoin, Rifampin, St John's Wort


May cause fetal harm based on animal studies. Advise females of reproductive potential to use effective contraception during treatment.
NOTE

Prior to initiating treatment, verify pregnancy status in females of reproductive potential.

Our database has 13 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top